ProCE Banner Activity


Experts Discuss Advances in the Use of BTK Inhibitors for the Treatment of Relapsed/Refractory MCL


Watch this on-demand webcast from a live webinar on the optimal use of BTK inhibitors in the management of patients with relapsed/refractory mantle cell lymphoma.

Physicians: Maximum of 2.00 AMA PRA Category 1 Credits

Released: March 20, 2023

Expiration: March 19, 2024

No longer available for credit.



Julie M. Vose

Julie M. Vose, MD, MBA

Newmann M. and Milde E. Harris Professor
Chief, Hematology/Oncology
Department of Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Marco Ladetto

Marco Ladetto, MD

Associate Professor in hematology
University of Eastern Piedmont
Director of SCDU Hematology Division
AO SS Antonio E Biagio e Cesare Arrigo
Alessandria, Piedmont, Italy

Max Topp

Max Topp, MD

Head of Hematology
Department of Hematology
Universitätsklinikum Würzburg
Würzburg, Germany

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by an educational grant from Lilly.


Target Audience

This globally focused educational program is intended for hematologists, medical oncologists, and other healthcare professionals who treat and manage patients with mantle cell lymphoma.

Program Learning Goal

The goal of this program is to improve the knowledge, confidence, competence, and performance of learners in selecting individualized treatments for patients with relapsed/refractory MCL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate emerging BTK inhibitor data in the treatment of MCL considering the potential impact of safety and efficacy results on clinical practice

  • Plan BTKi-based therapeutic strategies for patients with R/R MCL, taking into consideration global indications and recent practice-changing clinical trial results

  • Select and sequence therapy for patients with MCL who have developed resistance to or intolerance of covalent BTKi-based therapy to optimize clinical outcomes

  • Identify patients with MCL who may be eligible for ongoing clinical trials evaluating currently available and emerging BTKis and BTKi-based combinations


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Marco Ladetto, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, Amgen, AstraZeneca, Eusapharma, Gentili, Gilead/Kite, Incyte, Johnson & Johnson, Jazz, Lilly, Regeneron, Roche.  

Max Topp, MD, consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, Janssen, Kite, Roche.

Julie M. Vose, MD, MBA: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Caribou, Daiichi Sankyo, Genentech, Kite, Lilly, MEI Pharma, MorphoSys, Pharmacyclics, Seattle Genetics. 

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from March 20, 2023, through March 19, 2024:

  1. Create an account or Login at
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.